Brazil’s Fiocruz, after delay, starts production of AstraZeneca Covid-19 vaccine

RIO DE JANEIRO, BRAZIL – The vaccine produced with drugs imported from China has passed the necessary tests and 3.8 million doses can be expected to be handed over to the Health Ministry in Brasilia by the end of March.

The recent arrival of a shipment of raw materials to make 12.2 million doses of the AstraZeneca vaccine had raised new hopes for a vaccination breakthrough amid the rapid spread of the coronavirus in Brazil.

With Fiocruz, Brazil has a vaccine factory that is considered the largest in Latin America.

By mid-year, Fiocruz wants to produce 110 million doses of AstraZeneca’s coronavirus vaccine using imported pharmaceuticals.

In the second half of the year, thanks to technology transfers, it will be able to produce a further 110 million doses completely independently.

The South American country started vaccinations in January. So far, more than 11 million people have been proven to be infected with the coronavirus in Brazil. More than 266,000 patients have died as a result of the virus. Higher numbers have only been recorded in the United States and India.

Most recently, Brazil experienced its worst week in the pandemic to date, with around 10,000 coronavirus deaths in seven days.